Abstract Background: Acinetobacter baumannii infections in neonates are not uncommon but rarely studied. Methods: Clinical and molecular epidemiology of 40 patients with A. baumannii bacteremia in the neonatal intensive care units (NICUs) of a medical center from 2004 to 2014 was analyzed. Results: Multi-drug resistance was found in only 3 isolates (7.5%). Sequence types (STs) of A. baumannii defined by multilocus sequencing typing were diverse, and 72.4% identified isolates belonged to novel STs. Majority of the isolates were susceptible to antibiotics tested. Among the 3 imipenem-resistant A. baumannii (IRAB) isolates, 2 (66.7%) belonged to ST684, a novel ST. All of the 3 isolates were susceptible to tigecycline and colistin. The predominant mechanism of imipenem resistance in these neonatal isolates is ISAba1-bla OXA-80 , which has never been reported in Asia before. Most infected newborns were premature (95%), with very low birth weight (70% < 1500 g), prolonged intubation, usage of percutaneous central venous catheter (65%) and long-term usage of total parenteral nutrition or intravenous lipid (95%). IRAB infection, inappropriate initial therapy, 1-minute Apgar score and early onset infection within the first 10 days of life were found to correlate with mortality by log-rank test. Prior use of imipenem for at least 5 days and use of high frequency oscillation ventilation (HFOV) were statistically significant risk factors for acquiring IRAB infections.
Introduction
In the neonatal intensive care unit (NICU), Acinetobacter baumannii contributes to 0.2e6.9% of all bacteremia, 1, 2 and 8%e25% of all late onset sepsis caused by Gramnegative bacilli. 3, 4 Bacteremia caused by imipenemresistant A. baumannii (IRAB) has been associated with a higher mortality (46.0%) than bacteremia by imipenemsusceptible A. baumannii (ISAB) (28.3%) and other diagnoses of A. baumannii infection. 5 The mortality rate of neonates due to IRAB sepsis was 20.34% (12/59) at a medical center in central Taiwan. 6 In our previous study in adult patients, imipenem-resistant A. baumannii complex bacteremia showed a high mortality (69.9%), and was associated with prior use of broad-spectrum antibiotics for more than 5 days for treating ventilator-associated pneumonia before the occurrence of bacteremia. 7 However, there are few studies surveying risk factors of acquiring IRAB in neonates and we did not know how to prevent these fatal infections in newborns.
The predominant resistance mechanism to imipenem in A. baumannii isolates from adult patients from 1993 to 2007 in Taiwan was ISAba1ebla OXA-51-like . 8 Since 2006, Tn2006 (ISAba1ebla OXA-23 eISAba1) has been increasingly found in the clinical A. baumannii isolates and can be easily selected by antibiotic pressure from the use of imipenem or extended-spectrum cephalosporins. 8 However, imipenem resistance mechanisms in A. baumannii isolates from newborns and risk factors of IRAB remain unknown.
Multilocus sequence typing (MLST), a widely used technique for bacterial typing, was proven to provide unambiguous typing data for long-term and global A. baumannii epidemiological surveillance. 9 However, there is no published MLST data in clinical neonate A. baumannii isolates in Taiwan.
By comparing clinical presentations and molecular epidemiology of neonatal IRAB infections with those of ISAB infections, our aim was to identify risk factors of acquiring IRAB infections and those of mortality that may facilitate the interventions for the control of neonatal A. baumannii infections and thus improve their outcome.
Materials and methods

Study subjects and inclusion criteria
This study was approved by the Institutional Review Board (100-3592B). Charts were reviewed for NICU patients who were treated in Chang Gung Memorial Hospital (CGMH) from 2004 to 2014 and had !1 positive blood culture for A. baumannii, with symptoms and signs of infection. For patients with multiple episodes, only the first episode was included. Patients with incomplete medical records or with polymicrobial infections were excluded. The NICUs of CGMH, a tertiary medical center in northern Taiwan, contains a total of 47 beds with mechanical ventilator and 54 beds with special care nurseries.
Date collection and analysis
Clinical data including demographic characteristics, perinatal findings, presence of central venous catheters (CVCs), peripheral central venous catheters (PCVCs), umbilical vein catheters, history of surgery, total parenteral nutrition (TPN) and/or intravenous lipid usage, mechanical ventilation including nasal continuous positive airway pressure (NCPAP) and high frequency oscillation (HFO), previous antibiotic exposure duration, adequate prompt antibiotic treatment, and initial blood testing for white blood cell count and C-reactive protein, were collected and analyzed.
Definitions
Premature rupture of membranes (PROM) in pregnancy refers to rupture of membranes of the amniotic sac and chorion >18 h prior to the onset of labor, whereas preterm PROM refers to rupture of the membranes with a gestation of <37 weeks, >18 h prior to the onset of labor. Ventilator use was defined as ever having used a ventilator with intermittent mandatory ventilation, HFO and NCPAP mode. The usage of CVCs (central venous catheters) was defined as ever having used a peripheral CVC (PCVC), femoral CVC, or umbilical vein catheter. Apgar scores and chorioamnionitis were based on the latest updated diagnostic criteria in the standard textbook of neonatology. 10 Mortality was defined as infection-attributable death, wherein the criteria of death were met before the symptoms and signs of bacteremia were resolved and with at least a blood culture positive for A. baumannii.
11 Considering "time at risk" for acquiring resistance under antimicrobial selective pressure, prior exposure to antimicrobial agents was defined as at least 5 days of therapy during the 14 days before the isolation of A. baumannii. 7, 8, 12 Appropriate antimicrobial therapy was defined as administering patients with at least one antimicrobial agent, except aminoglycoside, susceptible in vitro, within 2 days after bacteremia onset. 11, 13 Culture detecting time was the interval (days) from culture sampling to reporting.
Bacterial isolates and antimicrobial susceptibility
Conventional biochemical tests and 16S-23S rRNA intergenic spacer region sequencing as described previously were used to characterize bacterial genospecies.
14 Antimicrobial susceptibility was determined by the disk diffusion method according to Clinical and Laboratory Standards Institute standards. 15 Minimum inhibitory concentration (MIC) of imipenem was further determined by Etest (Biomerieux, La Balmes les Grottes, France). The breakpoint for defining ISAB was an MIC 4 mg/L, and a breakpoint of !8 mg/L for IRAB, including both intermediately-resistant and resistant strains. 15 
Multilocus sequence typing
In order to survey clonal relationships, 26 isolates were randomly selected and methods of the Bartual's PubMLST was used. 16 16 Sequences were compared with the A. baumannii database at the MLST database (http://pubmlst.org/ abaumannii/) conducted by BLAST.
The eBURST algorithm (http://eburst.mlst.net/) was used to analyze the genetic relationships of sequence types. 16 Clonal complexes (CCs) were stringently defined as a cluster of STs having the same alleles at six among seven loci and containing at least two STs. 17 Novel CCs were named by STs of their founders.
All MLST results in this study were compared with our previous results in adult patients. 18 Polymerase chain reaction and sequencing Primers specific for resistance genes (bla , bla OXA-40 , bla OXA-51 , bla OXA-54 , bla OXA-58 , bla ADC-1 , bla ADC-29 , bla IMP-1 , bla VIM-1 , and bla VIM-2 ), insertion sequences (ISAba1, ISAba2, and ISAba3) were designed (Table 1) , and PCR amplification and sequence determination were performed as described previously. 7,8,18e21 Detection of the IS upstream of the bla gene was performed by PCR using a forward primer of the IS (ISAba1, ISAba2, and ISAba3) and a reverse primer of the bla gene (bla , bla OXA-51 , and bla OXA-58 ) ( Table 1 ).
Statistical analysis
Data analyses were performed using SPSS software, v. 17.0 (SPSS Inc., Chicago, IL, USA). The Chi-square test or Fisher's exact test was used when appropriate to compare proportions. The Wilcoxon rank sum test was used to compare continuous variables. Variables with a p value of less than 0.2 in the univariate analysis were added in a forward stepwise manner and selected to create the final model for multivariable analysis. We used KaplaneMeier method to construct survival curves and log-rank tests to assess differences of survival probabilities between patients infected by A. baumannii with different imipenem susceptibilities, between those given different treatments, between those having different Apgar score, and between those with different infection onset time. All statistical analyses were two-sided, and significance was set at p < 0.05. 
Results
Clinical isolates
Forty cases of A. baumannii bacteremia were identified in neonates admitted in the NICUs of CGMH between January 2004 and December 2014. The median gestational age and birth weight of all enrolled infants with A. baumannii bacteremia were 28 weeks and 1154 g respectively. The demographic characteristics of the cases are summarized in Table 2 . Imipenem resistance was found in only 3 isolates (7.5%). The bacteremia-related mortality was 5%. Most of the patients with A. baumannii infection had prolonged intubation, presence of PCVC (65%) and longer use of TPN or intravenous lipid (95%). The result of MLST showed diverse genotypes (Table 3) .
Sequence types, antimicrobial susceptibilities and PFGE genotypes
There were 16 novel STs found by the Bartual's PubMLST scheme in this study, including N-1 to N-16 (Table 3) . Most IRAB isolates (66.7%) belonged to ST684, a novel ST. ST684 isolates belonged to CC92 and were susceptible to tigecycline and colistin (100%) but 50% resistant to ampicillinsulbactam and 100% resistant to all other antibiotics tested. One isolate belonged to ST449, which was resistant to all antibiotics tested except tigecycline and colistin. All of the 3 IRAB showed full resistance to imipenem (MIC ! 16 mg/L). A total of 26 ISAB isolates were randomly selected from 37 ones for identifying their STs which were very diverse and belonged to 19 different STs (Table 3 ). All ISAB isolates
were susceptible to all antibiotics tested (MIC of imipenem: from 0.25 to 2 mg/L). All the ISAB were not MDRAB.
No temporal or geographic association among isolates
All isolates of A. baumannii were collected from neonates with bacteremia treated in the NICU of our hospital during an 11-year period. We have observed no temporal or geographic association among these isolates. We have further examined the clonal relationship of these isolates by MLST using the Bartual's PubMLST scheme. Three IRAB isolates belonged to 2 different STs. A total of 26 ISAB isolates were randomly selected from 37 isolates and genotyped. They showed very diverse STs (19 different STs). Taken together, there was no clonal spread or outbreaks in terms of A. baumannii bloodstream infection during the study period in the NICU of our hospital.
Imipenem resistance genes
For a total of 40 isolates, all isolates carried bla OXA-51-like . The bla OXA-23 gene (GenBank accession no. GQ861439.1) or bla OXA-58 gene was not found in any isolates. Among the 3 IRAB isolates, the upstream ISAba1 was found in 3 (100%) with bla OXA-80 (belonged to bla OXA-51-like ) ( Table 3 ). All of these isolates showed resistance to imipenem. None of the isolates carried bla OXA-40 /bla OXA-24, bla IMP-2 , bla VIM-1 , bla VIM-2, or bla NDM-1.
Clinical outcomes
Overall 30-day mortality was 5% (2/40). We used KaplaneMeier method to construct survival curves and log- rank tests to assess differences of survival probabilities between patients infected by IRAB and those infected by ISAB. Nearly 97.3% of patients with ISAB bacteremia survived through day 30, compared with only 66.7% with IRAB infection (p < 0.011, by log-rank test, Fig. 1A ). The same methods were used to assess differences of survival probabilities between patients given appropriate initial therapy and those given inappropriate therapy. Nearly 97.3% of patients with appropriate initial therapy survived through day 30, compared with only 66.7% with inappropriate therapy (p Z 0.001, by log-rank test, Fig. 1B) . We also assessed differences of survival probabilities between patients with 1-minute Apgar score !3 and those with 1-minute Apgar score <3. Nearly 97.3% of neonatal patients with 1-minute Apgar score !3 survived through day 30, compared with only 50% of those with 1-minute Apgar score <3 (p Z 0.001, by log-rank test, Fig. 1C) . Furthermore, all of the neonates with late onset infection after 10 days of life survived through day 30, compared with only 81.8% with early onset infection within the first 10 days of life (p Z 0.019, by log-rank test, Fig. 1D ).
Risk factor analysis
Risk factors for 30-day mortality were analyzed by comparing characteristics of nonsurvivors and survivors (Table 4) . After nonparametric statistical analysis, there were no significant risk factors associated with mortality identified (Table 4 ). Risk factors for newborns acquiring IRAB infections were analyzed by comparing characteristics of IRAB infections and ISAB infections (Table 5 ). After nonparametric statistics was performed, previous usage of imipenem and use of high frequency oscillation ventilation (HFOV) were significant risk factors for acquiring IRAB infections (Table 5 ).
Discussion
A. baumannii from neonatal patients belonged to diverse STs which are quite different from those of our adult patients. 18 In 29 MLST-checked isolates, only one isolate (3.4%) belonging to ST552 has been found in STs of A. baumannii from our previous adult patients. 18 Other 28 MLST-checked isolates identified belonged to 20 different STs which were never found in our previous adult patients. In detail, ST684, the main ST of IRAB in our neonatal patients, was not found in STs from our previous adult patients.
18 ST455, the main ST of IRAB in our adult patients, was never found in STs from neonatal patients. 18 CC92, the main CC in our previous adult patients, 18 was never found in any isolates from neonatal patients except for the 2 IRAB which belonged to ST684.
We traced the source of our neonatal isolates by searching MLST database website (http://pubmlst.org/ abaumannii/). Among 3 IRAB found in this study, 2 isolates (66.7%) belonged to ST684, a novel ST in the world, and one (33.3%) belonged to ST449, which has been found in 2 isolates from United States in 2003. Among 26 MLST-checked ISAB, 19 isolates (73.1%) belonged to novel STs, 5 belonged to ST373 (been found in China, Japan and Czech from 1993 to 2012), one belonged to 229 (been found in United States, Mexico and Brazil from 2007 to 2009) and one belonged to 552 (been found in our previous adult isolate). 18 The predominant imipenem resistance mechanism of IRAB from neonatal patients was ISAba1-bla OXA-80 which has never been found in all over the world except UK. 7, 8, 18, 22 The bla OXA-80 gene was modified from the bla OXA-66 gene (GenBank accession no. DQ923479) by a single nucleotide alternation which resulted in a single amino-acid change. 22 Interestingly, the bla OXA-66 gene contributed to most bla OXA-51-like gene in our previous adult isolates. 7, 8, 18 ISAba1e-bla OXA-51-like was the predominant mechanism of imipenem resistance in Taiwan from 1993 to 2007. 23e25 However, we found ISAba1ebla OXA-23 has replaced ISAba1ebla OXA-51-like as the main resistance mechanism in Taiwan in 2009. 7, 8, 18 However, Tn2006, the main predominant imipenem resistance mechanism of IRAB in our previous adult patients, 7, 8, 18 was never found in IRAB of this neonate study. The bla OXA-51-like genes are located in chromosome in all A. baumannii strains, 26 whereas the bla OXA-23-like genes can be either chromosomally or plasmid located. 27, 28 The bla OXA-23 gene associated with Tn2006 in an AbaR4-type resistance island capable of transposing from bacteria to bacteria could be located on the chromosome or a plasmid. 27, 28 It seemed that Tn2006 in an AbaR4-type resistance island have not yet transposed to common STs in neonatal patients in current Taiwan.
Since neonate STs differed from adult STs, clinical risk factors for mortality or acquiring IRAB might be different. In our study, IRAB infection, inappropriate therapy, 1-Minute Apgar score and early onset infection within the first 10 days of life have found to correlate with mortality by log-rank test. The sepsis-related mortality has also been found to be higher in early-onset sepsis within the first 7 days of life (10%) than in late-onset sepsis (7%) in a previous neonate study. 2 Since all our IRAB were also resistant to three or more classes of antimicrobials, they also meet the criteria of multi-drug resistant A. baumannii (MDRAB). 6 In a previous study in central Taiwan, the mortality rate due to MDRAB sepsis was 20.34% (12/59) which was lower than our mortality due to MDRAB (33.3%). In this previous study, the statistically significant risk factors for mortality due to MDRAB infection were early onset (being infected with MDRAB within 7 days of admission to the NICU), use of umbilical vein catheters, neutropenia (absolute neutrophil count < 1500/mm3), thrombocytopenia (platelet count < 100,000/mm 3 ), and a delay in initiating adequate antibiotic treatment. 6 The MDRAB outbreak in a NICU in United States was found only in extremely low birth weight (<750 g) neonates, at extremely premature ( 26 weeks gestational) age, and in early onsetperiod ( 7 days postnatal age at the time of exposure), suggesting that invasive A. baumannii has a special affinity for damaged or nonkeratinized immature skin in developmentally immature immunologic hosts. 29 Like this previous result, most of the neonates with A. baumannii infection in our study were premature (95%) and had very low birth weight (70% < 1500 g), prolonged intubation, presence of percutaneous central venous catheter (PCVC) (65%) and longer usage of TPN or intravenous lipid (95%). Our result was also similar to that of a previous study in Palestine in which risk factors for acquiring A. baumannii were weight <1500 g (odds ratio (OR) 3.89, p < 0.001), age <7 days (OR 2.33, p Z 0.027), median hospitalization of Z 20 days (OR 3.1, p Z 0.003), mechanical ventilation (OR 3.5, p Z 0.001), use of a central venous catheter (CVC; OR 10.5, p < 0.001), and prior antibiotic use (OR 4.85, p Z 0.003). 30 In this study, the overall mortality was also significantly increased in the infection group (overall mortality 37.5% in cases vs. 12% in uninfected controls; OR 4.4, p Z 0.001) 30 , and, like our results, the multidrug-resistant type was significantly associated with death in the neonates compared with susceptible type (60% vs 24%, p Z 0.023). 30 In a previous study in Taiwan, in comparison to matched and uninfected controls, infants with A baumannii were more likely to have had a central vascular catheter (CVC) (p Z 0.009), use of TPN (p Z 0.021), longer duration of ventilator use (p Z 0.002), and hospitalization (p Z 0.010). 3 Compared with E coli or Klebsiella bacteremia, infants with A baumannii bacteremia had lower birth weight (median of 1090 g vs 1300 g, p Z 0.044) and a higher rate of CVC and TPN use (both p < 0.001) at the time of infection. 3 These results were similar to those of our study. In conclusion, identified STs of A. baumannii from neonatal patients were diverse and quite different from those from adult patients. Most (21/29) checked isolates belonged to novel STs in the world. The predominant mechanism of imipenem resistance from neonatal patients was ISAba1-bla OXA-80 which has never been reported in Taiwan and modified from the bla OXA-66 gene by a single amino-acid change. Tn2006 in an AbaR4-type resistance island, a predominant resistance mechanism in adults, has not yet transposed to common STs in neonatal isolates in Taiwan. Continued surveillance is necessary. Preventing IRAB infection, inappropriate initial therapy, 1-Minute Apgar score and early onset infection within the first 10 days of life significantly correlated with mortality by logrank test. For reducing mortality, it is crucial to consider giving colistin or tigecycline within 2 days for high risk neonates for IRAB infections such as newborns with previous usage of imipenem or HFOV. Restricting unnecessary usage of imipenem and HFOV is crucial for preventing IRAB infections in newborns.
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